US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi NVO 2x Daily ETF

13.75

-0.0756-0.55%

Post-market: 13.820.0756+0.55%16:10 EDT

Volume:16

Turnover:225

Market Cap:206.22K

PE:- -

High:13.75

Open:13.82

Low:13.75

Close:13.82

52wk High:27.19

52wk Low:13.75

Shares:15.00K

Float Shares:15.00K

Volume Ratio:0.18

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novo Nordisk's Weight-Loss, Diabetes Drug Candidate Meets Primary Goals

MT Newswires Live

Goldman Sachs Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Why Is Novo Stock (NVO) Falling in Pre-Market Today, September 21?

Novo Nordisk Drops Over 7% Pre-Market as Wegovy Sales Miss Expectations

Market Chatter: Novo Nordisk Urged by Shareholders to Develop New Medicines, Pursue Acquisitions

MT Newswires Live

Novo Nordisk Aims for $23 Billion in 2035 Pipeline Sales

MT Newswires Live

Novo Nordisk Stock Tumbles as Ozempic Maker Sets Out 2030 Goals

Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years

Novo Unveils Ambitious Pipeline Plans, Yet Shares Slide 6% as Investors Seek More

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

Health Advisory: Avoid Misusing Weight-Loss Medications, Prioritize Evaluation Before Treatment

Novo Nordisk’s Once-Weekly Insulin Study Signals a New Phase for Diabetes Care

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Novo Nordisk's Sogroya Gets Positive EU Opinion for Children With Idiopathic Short Stature

MT Newswires Live

Sandoz Faces Uncertain Opportunity with New Drug Approval in Canada

Sandoz Receives Marketing Authorization for Generic Version of Ozempic in Canada

MT Newswires Live

When Weight Loss Isn't the Goal of Taking a GLP-1

Novo Nordisk Wins EMA Panel Backing for New Haemophilia A Therapy FREHEMGO

Novo Nordisk A/S Stock (NVO) Moved Up by 3.02% on Sep 17: What Signal Does It Send?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NVOC/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVOC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","market":"US","secType":"STK","nameCN":"Corgi NVO 2x Daily ETF","latestPrice":13.7479,"timestamp":1790971200000,"preClose":13.8235,"halted":0,"volume":16,"hourTrading":{"tag":"盘后","latestPrice":13.8235,"preClose":13.7479,"latestTime":"16:10 EDT","volume":6,"amount":82.4874,"timestamp":1790971804945,"change":0.0756,"changeRate":0.005499,"amplitude":0},"delay":0,"changeRate":-0.005468947806271904,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"Market Closed","change":-0.0756,"latestTime":"10-02 16:00:00 EDT","open":13.8235,"high":13.7479,"low":13.7479,"amount":225,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1784001600000,"exchange":"CBOE","adjPreClose":13.8235,"nav":13.82,"aum":207300,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":13.8235,"preClose":13.7479,"latestTime":"16:10 EDT","volume":6,"amount":82.4874,"timestamp":1790971804945,"change":0.0756,"changeRate":0.005499,"amplitude":0},"volumeRatio":0.1769910525491966},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.1769910525491966,"shares":15000,"dividePrice":0,"high":13.7479,"amplitude":0,"preClose":13.8235,"low":13.7479,"week52Low":13.7479,"pbRate":"--","week52High":27.1863,"institutionHeld":0,"latestPrice":13.7479,"eps":0,"divideRate":0,"volume":16,"delay":0,"ttmEps":0,"open":13.8235,"prevYearClose":24.92,"prevWeekClose":14.9092,"prevMonthClose":14.2471,"prevQuarterClose":14.2471,"fiveDayClose":14.9092,"twentyDayClose":22.7613},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOC\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669168766","title":"Novo Nordisk's Weight-Loss, Diabetes Drug Candidate Meets Primary Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2669168766","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669168766?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:46","pubTimestamp":1789991192,"startTime":"0","endTime":"0","summary":"Novo Nordisk's  investigational once-weekly weight-loss and diabetes treatment CagriSema was superior to tirzepatide and met its primary superiority endpoint in two phase 3 trials, respectively, the company said Monday.In one study, CagriSema achieved an average weight loss of 12.4%, compared with 9.1% for tirzepatide, the company said.In the other study, CagriSema provided a weight reduction of 21% versus 2% for a placebo, the company said. CagriSema also showed improvements compared with the placebo in other prespecified supportive endpoints including blood pressure, waist-to-height ratio, and fasting lipid profile, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","NVOX","BK4599","NVOC","OZEM","NVO","PPH","THNR","IE00BZ1G4Q59.USD","BK4585","BK4532","IE00BKVL7J92.USD","BK4007","LU0154236417.USD","LU1093756168.USD","NVOH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669168498","title":"Goldman Sachs Sticks to Their Hold Rating for Novo Nordisk (0QIU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669168498","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669168498?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:25","pubTimestamp":1789989926,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst James Quigley maintained a Hold rating on Novo Nordisk today and set a price target of DKK285.00. According to TipRanks, Quig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-novo-nordisk-0qiu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-novo-nordisk-0qiu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","BK4588","LU1093756325.SGD","BK4599","OZEM","THNR","NVO","NVOH","BK4007","NVOX","IE00BZ1G4Q59.USD","LU0154236417.USD","NVOC","PPH","BK4585","BK4532","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669157222","title":"Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157222","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669157222?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:44","pubTimestamp":1789987466,"startTime":"0","endTime":"0","summary":"Novo says its next-gen obesity drug tops Lilly rival in late-stage studySept 21 (Reuters)-Novo NordiskNOVOb.COsaid on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly'sLLY.Ndrug.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4N45D0OB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU1057294990.SGD","LU0133085943.USD","LU1291159041.SGD","SGXZ51526630.SGD","LU1551013425.SGD","LU0943347566.SGD","ELIS","LU1983299246.USD","LU2471134879.HKD","LU2168564065.EUR","LU0114720955.EUR","LU0203201768.USD","LU2237443549.SGD","LU0203202063.USD","LU1868836757.USD","LU0256863902.USD","LU2237443978.SGD","SG9999014898.SGD","LU2361044865.SGD","SG9999015952.SGD","LU0320765059.SGD","LU2023250330.USD","LU0238689110.USD","LU2324357040.USD","LU1989771016.USD","LU2237443465.HKD","LU0823434740.USD","OZEM","LU1280957306.USD","SGXZ99366536.SGD","LU0154236417.USD","LU0820561818.USD","LU0820561909.HKD","THNR","LU1061106388.HKD","LU2456880835.USD","LU2264538146.SGD","BK4534","LU0266013472.USD","TMED","LU0320765992.SGD","LU2552382132.HKD","LU0354030511.USD","LU2461242641.AUD","IE00BJJMRY28.SGD","LU0471298694.HKD","LU0234572021.USD","LU0353189763.USD","SG9999015945.SGD","LU0820562030.AUD","SG9999017495.SGD","LU2417539215.USD","SG9999015978.USD","LU0174119429.USD","IE00BWXC8680.SGD","LU1868836591.USD","LU2462591350.SGD","SG9999015986.USD","LU1623119135.USD","LU0823416689.USD","SGXZ81514606.USD","LU2552382058.USD","LU2552382215.SGD","LU2023250504.SGD","LU2357305700.SGD","LU0061475181.USD","LU2746668974.SGD","LU2168564222.USD","LU2213496289.HKD","LU0094547139.USD","LU1093756168.USD","BK4532","LU2106854487.HKD","LU2168564149.EUR","IE00BFSS8Q28.SGD","LLY","MHIP","ELIL","LU2271345857.HKD","LU0683600562.USD","BK4516","LU0006306889.USD","FTXH","IE00BFTCPJ56.SGD","LU2237443622.USD","LU0158827781.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","IE00BJT1NW94.SGD","LU0708995401.HKD","NVOH","LU0786609619.USD","LU0471298777.SGD","LU0823434583.USD","MEDI","LU2089984988.USD","LU1069344957.HKD","JDOC","LU2111349929.HKD","LU2361045086.USD","NVO","IE00BKDWB100.SGD","LU1064131342.USD","LU1974910355.USD","LU1988902786.USD","LU2028103732.USD","LU2746668461.USD","IE00BK4W5M84.HKD","LU2023251221.USD","LU1127390331.HKD","LU0289739699.SGD","LU0109394709.USD","IYH","LU0456855351.SGD","LU1093756325.SGD","SGXZ31699556.SGD","LU0345770993.USD","SG9999018865.SGD","IE00B4JS1V06.HKD","LU0432979614.USD","CANC","HRTS","IE00BKVL7J92.USD","ILDR","IE00BK4W5L77.USD","LU2237443895.HKD","LU0225283273.USD","LU1979441026.SGD","IE00B1XK9C88.USD","XLV","LU2462157665.USD","SG9999014906.USD","RXL","LU0256863811.USD","LU0353189680.USD","LU2471134523.USD","LU0672654240.SGD","PJP","LU1917777945.USD","LU2087625088.SGD","LU1145028129.USD","LU2237443382.USD","LU0210536198.USD","LU0385154629.USD","SG9999013999.USD","LU0198837287.USD","LU0689472784.USD","LU0417517546.SGD","LU2491049909.HKD","LU2168564495.EUR","IE00BJLML261.HKD","IE00B1BXHZ80.USD","LU1868837136.USD","LU0787776722.HKD","LU0109391861.USD","LU0964807845.USD","SG9999001176.SGD","LU0466842654.USD","AGNG","LU2063271972.USD","LU1548497426.USD","LU2750360997.AUD","IE00BN29S564.USD","LU0058720904.USD","LU2211815571.USD","LU1691799644.USD","BK4581","LLII","LU0316494557.USD","LU1551013342.USD","LU1868837300.USD","LU2468319806.SGD","GB00BDT5M118.USD","LU2108987350.USD","LU2471134796.USD","TRUH","LU2089283258.USD","IE0009355771.USD","IXJ","LU2237438978.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1804176565.USD","LU0323591593.USD","LU1323610961.USD","SG9999014880.SGD","LU2168563687.JPY","SGXZ57979304.SGD","LU2089284900.SGD","LU0889565916.HKD","BK4588","LU1267930730.SGD","LU1035775433.USD","LU1712237335.SGD","LU0079474960.USD","IE0001KFT4U8.USD","IE0004445015.USD","LU1720051108.HKD","MEDX","LU0882574055.USD","LU2750360641.GBP","IE00B7KXQ091.USD","LU0097036916.USD","LU2756315318.SGD","CURE","SG9999001176.USD","GDOC","LLYX","LU0640476718.USD","LU0345770308.USD","LU1629891620.HKD","LU1720051017.SGD","SG9999014914.USD","LU2236285917.USD","SG9999018857.SGD","FHLC","LU2360106947.USD","BK4007","BK4533","IE00BFSS7M15.SGD","LU0122379950.USD","LU0882574139.USD","LU2491050071.SGD","LU1023059063.AUD","LU2896262040.SGD","LU2361044949.HKD","WDNA","LU1814569148.SGD","IE00BJJMRX11.SGD","LU1868836914.USD","LU0354030438.USD","LLYZ","NVOX","VHT","IE00B775H168.HKD","LU2471134952.CNY","IHE","LU2491050154.USD","LU0096364046.USD","LU1232071149.USD","PPH","LU2602419157.SGD","IE0004445239.USD","LU0158827948.USD","IE00BKPKM429.USD","LU1366192091.USD","BK4585","BK4599","LU2756315664.SGD","NVOC","IE00BJJMRZ35.SGD","IE0005OL40V9.USD","LU2265009873.SGD","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669506111","title":"Why Is Novo Stock (NVO) Falling in Pre-Market Today, September 21?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669506111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669506111?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:40","pubTimestamp":1789987202,"startTime":"0","endTime":"0","summary":"Shares of Danish drug giant Novo ($NVO) dropped more than 5% to around $41 in Monday’s pre-market session. The decline came after CEO Mike Doustdar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novo-stock-nvo-is-falling-in-pre-market-today-september-21-heres-why?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novo-stock-nvo-is-falling-in-pre-market-today-september-21-heres-why?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","NVOH","IE00BZ1G4Q59.USD","LU0154236417.USD","NVO","THNR","LU1093756325.SGD","BK4007","BK4532","LU1093756168.USD","OZEM","BK4585","PPH","NVOC","BK4599","NVOX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669152858","title":"Novo Nordisk Drops Over 7% Pre-Market as Wegovy Sales Miss Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2669152858","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669152858?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:49","pubTimestamp":1789984163,"startTime":"0","endTime":"0","summary":"TradingKey - On September 21, Novo Nordisk (NVO) dropped over 7% at one point in US pre-market trading. According to the company's latest financial results, while full-year sales and profit guidance improved from previous projections, sales performance of its core weight-loss drug Wegovy still missed market expectations, serving as the primary drag on the stock.","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262178042-novo-nordisk-slides-premarket-wegovy-sales-miss-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","NVOH","LU1093756168.USD","NVOC","IE00BZ1G4Q59.USD","LU0154236417.USD","PPH","IE00BKVL7J92.USD","BK4588","BK4585","LU1093756325.SGD","OZEM","BK4599","NVOX","THNR","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154261","title":"Market Chatter: Novo Nordisk Urged by Shareholders to Develop New Medicines, Pursue Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154261","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669154261?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:47","pubTimestamp":1789984022,"startTime":"0","endTime":"0","summary":"Novo Nordisk  is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported Sunday, citing the company's investors.The Danish pharmaceutical giant's chief executive, Mike Doustdar, is under pressure to demonstrate that Novo can regain ground lost to key rival Eli Lilly  in the obesity drug market, according to the report.Novo will discuss topics, including research and development, at its capital markets day scheduled for Monday, the company said in a statement e-mailed to MT Newswires.Novo shares were down 6.1% in premarket activity Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4588","BK4585","NVOX","PPH","IE00BKVL7J92.USD","BK4532","IE00BZ1G4Q59.USD","BK4599","NVO","NVOC","NVOH","THNR","LU1093756325.SGD","LU1093756168.USD","OZEM","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154579","title":"Novo Nordisk Aims for $23 Billion in 2035 Pipeline Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154579","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669154579?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:38","pubTimestamp":1789983492,"startTime":"0","endTime":"0","summary":"Novo Nordisk  on Monday outlined long-term financial and pipeline targets, including plans for 150 billion Danish kroner  in pipeline sales in 2035 and the launch of at least five multi-blockbusters by 2030.The Danish company said it is targeting compounded annual revenue growth rates from 2026 to 2030 in line with industry peers.Novo Nordisk aims to scale capacity to serve 10 times more people with obesity on oral GLP-1s and more than 60 million patients by 2030, it said.The drugmaker also said it envisions maintaining a \"broadly stable\" operating margin and an \"attractive\" dividend per share.Shares of the company were down 6% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","PPH","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4588","THNR","LU1093756168.USD","NVO","BK4532","BK4585","BK4007","BK4599","NVOX","OZEM","NVOH","IE00BKVL7J92.USD","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669748159","title":"Novo Nordisk Stock Tumbles as Ozempic Maker Sets Out 2030 Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2669748159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669748159?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:58","pubTimestamp":1789981080,"startTime":"0","endTime":"0","summary":"Danish drugmaker says it aims to grow revenue in line with its leading rivalsNovo Nordisk CEO Mike Doustdar poses for a photo at Novo Nordisk headquarters in Bagsvaerd on August 5, 2026. The stock tum","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPH","BK4532","NVO","BK4588","NVOX","IE00BZ1G4Q59.USD","LU1093756168.USD","OZEM","BK4599","BK4007","LU0154236417.USD","BK4585","THNR","NVOC","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669151392","title":"Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2669151392","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669151392?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:58","pubTimestamp":1789981080,"startTime":"0","endTime":"0","summary":"Novo Nordisk aims to launch several new blockbuster drugs in the next few years while expanding into further treatment areas, part of a new plan to revive growth that the Ozempic manufacturer outlined","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","NVOX","OZEM","NVO","BK4585","IE00BKVL7J92.USD","NVOC","PPH","THNR","BK4599","BK4007","NVOH","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189776501","title":"Novo Unveils Ambitious Pipeline Plans, Yet Shares Slide 6% as Investors Seek More","url":"https://stock-news.laohu8.com/highlight/detail?id=1189776501","media":"Trading Random","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189776501?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:22","pubTimestamp":1789978936,"startTime":"0","endTime":"0","summary":"Novo Nordisk A/S announced intentions to introduce more than five blockbuster medications by 2030, aiming to maintain its edge in the fiercely competitive weight-loss treatment sector.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Novo Unveils Ambitious Pipeline Plans, Yet Shares Slide as Investors Seek More","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","NVOH","NVOC","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668184620","title":"Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2668184620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668184620?lang=en_us&edition=fundamental","pubTime":"2026-09-20 22:55","pubTimestamp":1789916110,"startTime":"0","endTime":"0","summary":"Dozens of people are suing Novo Nordisk (NVO), claiming its weight-loss and diabetes drugs Wegovey and Ozempic caused their nonarteritic anterior i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-novo-sued-over-risk-of-sudden-vision-loss-wsj-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-novo-sued-over-risk-of-sudden-vision-loss-wsj-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TMED","IE0004445239.USD","IE0005OL40V9.USD","SG9999014880.SGD","LU0786609619.USD","ELIL","LU1868836591.USD","ILDR","LU0058720904.USD","LU0353189680.USD","LU0787776722.HKD","NVO","LU1280957306.USD","LU1366192091.USD","LU0320765059.SGD","IE00B4R5TH58.HKD","LU2746668974.SGD","LU0466842654.USD","SGXZ31699556.SGD","LU2168564149.EUR","BK4581","LU0889565916.HKD","GDOC","LU2028103732.USD","IE00BKVL7J92.USD","TRUH","LU1804176565.USD","LU2237438978.USD","LU0203202063.USD","LU0174119429.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00B775H168.HKD","LU0823416689.USD","LU2236285917.USD","IE00BJJMRY28.SGD","LU2361045086.USD","LU2491050071.SGD","SG9999014906.USD","BK4533","SGXZ51526630.SGD","LU1057294990.SGD","LU0882574055.USD","LU2417539215.USD","LU0471298694.HKD","LU2108987350.USD","LU2756315318.SGD","LU2089283258.USD","LU2361044949.HKD","LU2471134952.CNY","LU0689472784.USD","IE00BWXC8680.SGD","BK4516","SG9999017495.SGD","BK4534","LU2168564065.EUR","SG9999015978.USD","SGXZ99366536.SGD","LU0943347566.SGD","LU2023250504.SGD","LU1623119135.USD","SG9999001176.SGD","LU1127390331.HKD","LU1232071149.USD","LU0708995401.HKD","LU2552382215.SGD","LU1988902786.USD","LU2265009873.SGD","NVOH","LU2361044865.SGD","LU2112291526.USD","LU0109394709.USD","LU0354030511.USD","LU1267930730.SGD","LU0061475181.USD","MEDX","LU0096364046.USD","LU2756315664.SGD","IE00BJJMRX11.SGD","LU0203201768.USD","IE00BJLML261.HKD","LU2746668461.USD","LU0154236417.USD","LU1548497426.USD","LU1989771016.USD","LU0225283273.USD","IE00B7KXQ091.USD","LU2471134523.USD","LU0079474960.USD","LU1720051017.SGD","LU2461242641.AUD","IXJ","IE0009355771.USD","LU0158827948.USD","VHT","LU0256863902.USD","FHLC","FTXH","LU0672654240.SGD","LU0097036916.USD","IE00BJT1NW94.SGD","LU2471134879.HKD","LU2360106947.USD","BK4007","LU0114720955.EUR","GB00BDT5M118.USD","LU0133085943.USD","LU0345770308.USD","LU2168564222.USD","LU2462157665.USD","LU2750360997.AUD","LU0106261372.USD","LU0266013472.USD","LU2111349929.HKD","SG9999013999.USD","LU1023059063.AUD","SG9999018865.SGD","LU2552382132.HKD","LU0234572021.USD","LU2462591350.SGD","IE00BFTCPJ56.SGD","OZEM","LU2168563687.JPY","LU2237443382.USD","SG9999014898.SGD","IE00B1BXHZ80.USD","IE00BKPKM429.USD","LU0964807845.USD","LU1093756325.SGD","LU2264538146.SGD","LU0210536198.USD","PPH","LU2023250330.USD","IHE","LU2237443465.HKD","LU1061106388.HKD","LU0823434740.USD","LU1720051108.HKD","JDOC","AGNG","IE0001KFT4U8.USD","LU2468319806.SGD","LU0683600562.USD","LU1069344957.HKD","IE00B4JS1V06.HKD","LU2089984988.USD","LU0256863811.USD","LU1868837300.USD","LU2168564495.EUR","IE00BK4W5L77.USD","NVOX","SG9999014914.USD","LU0820561909.HKD","LU2491049909.HKD","LU1868836914.USD","LU2211815571.USD","LU2213496289.HKD","LU1323610961.USD","SG9999018857.SGD","SGXZ57979304.SGD","LLYZ","LU0417517546.SGD","CANC","THNR","SG9999015945.SGD","LU2023251221.USD","LU1868836757.USD","LU2271345857.HKD","LU2471134796.USD","CURE","LU1629891620.HKD","LU2602419157.SGD","BK4599","LU0323591593.USD","MEDI","LLII","LU1974910355.USD","LU1064131342.USD","LU1035775433.USD","LU1712237335.SGD","LU0823434583.USD","IYH","LU0320765992.SGD","LU0432979614.USD","IE00BKDWB100.SGD","LU2357305700.SGD","ELIS","IE00BFSS8Q28.SGD","SG9999015952.SGD","LU2087625088.SGD","LU2896262040.SGD","LU1983299246.USD","LLY","LU1814569148.SGD","LU2750360641.GBP","LU1691799644.USD","LU2237443895.HKD","WDNA","PJP","LU0122379950.USD","LU0471298777.SGD","SGXZ81514606.USD","LU1291159041.SGD","LU0385154629.USD","LU0353189763.USD","LU0456855351.SGD","LU2456880835.USD","BK4585","LU1145028129.USD","LU1868837136.USD","LU1551013425.SGD","LU1093756168.USD","LU2324357040.USD","LU2552382058.USD","LU2237443549.SGD","HRTS","IE00BFSS7M15.SGD","IE00BJJMRZ35.SGD","BK4532","RXL","SG9999001176.USD","IE00B2B36J28.USD","LU1551013342.USD","LU0238689110.USD","LU2491050154.USD","BK4588","LU0109391861.USD","LU1979441026.SGD","LU0198837287.USD","LU2106854487.HKD","IE0004445015.USD","NVOC","LU0006306889.USD","LU0820561818.USD","LU0820562030.AUD","IE00BN29S564.USD","LU1917777945.USD","MHIP","LU0158827781.USD","LU0640476718.USD","LU2237443978.SGD","LU0354030438.USD","LU0882574139.USD","LU2089284900.SGD","IE00B1XK9C88.USD","IE00BK4W5M84.HKD","XLV","LU0316494557.USD","LLYX","LU2237443622.USD","SG9999015986.USD","LU2063271972.USD","LU0345770993.USD","LU0094547139.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195583160","title":"Health Advisory: Avoid Misusing Weight-Loss Medications, Prioritize Evaluation Before Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1195583160","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195583160?lang=en_us&edition=fundamental","pubTime":"2026-09-19 16:50","pubTimestamp":1789807829,"startTime":"0","endTime":"0","summary":"This is a public service announcement from the local market regulatory authority. All works published on this website that indicate their source or author as relevant government bodies or departments...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOC","NBDS","PJP","IYH","FXH","CURE","MEDI","PINK","FHLC","RSPH","NVOX","TRUH","THNR","XLVI","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668092736","title":"Novo Nordisk’s Once-Weekly Insulin Study Signals a New Phase for Diabetes Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2668092736","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668092736?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:31","pubTimestamp":1789749071,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. This new Novo Nordisk study, officially titled “A Real-world, Multi-centre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-once-weekly-insulin-study-signals-a-new-phase-for-diabetes-care?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-once-weekly-insulin-study-signals-a-new-phase-for-diabetes-care?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","BK4532","NVOH","NVO","IE00BKVL7J92.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","NVOX","OZEM","PPH","BK4007","BK4599","BK4588","THNR","BK4585","LU0154236417.USD","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668174922","title":"Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2668174922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668174922?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:02","pubTimestamp":1789747320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B rose 0.8% to DKK281.55 Friday on what proved to be an overall poor trading session for the stock market, with the OMX Nordic 40 Index falling 0.7% to 2,654.97.This was the stock's second consecutive day of gains.The company closed DKK128.40 below its 52-week high of DKK409.95, which the company achieved on January 23, 2026.Trading volume was 9,279,685, compared to the 50-day average trading volume of 4,148,734.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","BK4588","IE00BKVL7J92.USD","BK4585","BK5011","0QIU.UK","BK4599","IE00BZ1G4Q59.USD","BK4007","LU1093756168.USD","NVO","NVOX","PPH","NVOC","THNR","LU0154236417.USD","BK4532","OZEM","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668014928","title":"Novo Nordisk's Sogroya Gets Positive EU Opinion for Children With Idiopathic Short Stature","url":"https://stock-news.laohu8.com/highlight/detail?id=2668014928","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668014928?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:47","pubTimestamp":1789732031,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Friday the European Medicines Agency's CHMP recommended once-weekly Sogroya for children with idiopathic short stature and persistent growth disturbance.If approved by the European Commission, Sogroya would become the first and only growth hormone treatment approved for idiopathic short stature in the EU, the company said.The recommendation follows earlier CHMP support for Sogroya in children born small for gestational age and those with Noonan syndrome, it added.The European Commission's decision on marketing authorization covering all three indications is expected later this year, Novo Nordisk said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOH","THNR","BK4532","LU0154236417.USD","IE00BKVL7J92.USD","NVO","BK4599","NVOX","OZEM","BK4588","NVOC","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","PPH","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668941012","title":"Sandoz Faces Uncertain Opportunity with New Drug Approval in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2668941012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668941012?lang=en_us&edition=fundamental","pubTime":"2026-09-18 17:18","pubTimestamp":1789723080,"startTime":"0","endTime":"0","summary":"0918 GMT - Sandoz Group's approval for a generic version of Novo Nordisk's Ozempic in Canada is positive, but it is difficult to assess how big of a boost this will be for the Swiss generic-drug manufacturer, RBC Capital Markets' Harry Sephton says. \"The overall generic opportunity is uncertain given we expect Novo to compete on price and it likely has the lowest cost of production, additionally it has shown willingness to compete in Canada with the launch of its own authorized generics Plosbrio and Poviztra,\" the analyst says in a research note. The Canadian market is large, with the Ozempic market estimated at around $1 billion and the total GLP-1 market at $2.6 billion, RBC says. Sandoz shares rise 2.7%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SDZXF","NVOH","BK4532","NVOC","PPH","BK4585","NVO","BK4599","OZEM","LU0154236417.USD","NVOX","IE00BKVL7J92.USD","THNR","BK4007","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668949215","title":"Sandoz Receives Marketing Authorization for Generic Version of Ozempic in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2668949215","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668949215?lang=en_us&edition=fundamental","pubTime":"2026-09-18 16:45","pubTimestamp":1789721117,"startTime":"0","endTime":"0","summary":"Sandoz has received Health Canada's marketing authorization for its Semaglutide product, which is a generic version of Novo Nordisk's  Ozempic, according to a Friday statement.The approval expands patient access to semaglutide treatment in Canada, Sandoz said.Sandoz said the weekly injection is approved for adults with type 2 diabetes and will be offered in three strengths across two pen devices.According to the company, the US Food and Drug Administration has also recently accepted its application for the in-house development of generic tirzepatide, and the Owozy semaglutide product, for which it holds commercial rights, has been approved in Brazil.Sandoz said the approval will not alter its 2026 financial outlook, with no meaningful contribution from generic semaglutide expected this year.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","SDZNY","BK4532","NVOX","OZEM","NVO","BK4585","IE00BKVL7J92.USD","NVOC","PPH","THNR","BK4599","BK4007","NVOH","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668915626","title":"When Weight Loss Isn't the Goal of Taking a GLP-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2668915626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668915626?lang=en_us&edition=fundamental","pubTime":"2026-09-18 09:00","pubTimestamp":1789693200,"startTime":"0","endTime":"0","summary":"At 5 feet 11 inches and 138 pounds, Ali Balkey has always been thin.So it might seem surprising that the 41-year-old Dallas, Texas real-estate investor says she has been taking a compounded version of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360106947.USD","IE00BZ1G4Q59.USD","CURE","LU0122379950.USD","IE00BFSS8Q28.SGD","LU0787776722.HKD","LU1623119135.USD","LU0114720955.EUR","LU0266013472.USD","LU1551013425.SGD","LU0672654240.SGD","LU0354030511.USD","IE0004445015.USD","LU2213496289.HKD","LU0471298694.HKD","LU2168563687.JPY","LU0432979614.USD","LU0203201768.USD","LU1868836591.USD","SG9999018857.SGD","RXL","LU2237443465.HKD","NVOX","IE00BJJMRZ35.SGD","LU0234572021.USD","LU2168564065.EUR","IE0001KFT4U8.USD","LU0256863811.USD","BK4585","LU0820561909.HKD","LU1061106388.HKD","LLII","LU2028103732.USD","IE00B4R5TH58.HKD","LU2324357040.USD","LU2211815571.USD","SG9999018865.SGD","LU0323591593.USD","LU0786609619.USD","LU0708995401.HKD","LU1974910355.USD","SG9999017495.SGD","LU0689472784.USD","IE00B1XK9C88.USD","LU0203202063.USD","IE00BJT1NW94.SGD","IE00BJJMRY28.SGD","LU0964807845.USD","LU1868836757.USD","IE00BJJMRX11.SGD","PPH","SG9999001176.USD","LU0943347566.SGD","BK4581","BK4516","LU2361044865.SGD","LU2264538146.SGD","LU2087625088.SGD","IE00BJLML261.HKD","LU2089283258.USD","LU0466842654.USD","LU2491050071.SGD","PJP","LU2106854487.HKD","LU2471134523.USD","SG9999014880.SGD","IE00BK4W5M84.HKD","LU0882574055.USD","LU0210536198.USD","LU2168564495.EUR","LU0289739699.SGD","LU0109391861.USD","LU2746668974.SGD","SGXZ99366536.SGD","TMED","LU1989771016.USD","SG9999015978.USD","MEDX","LU2552382215.SGD","LU1323610961.USD","LU1093756168.USD","LU1291159041.SGD","IYH","LU1035775433.USD","LU1691799644.USD","LU0096364046.USD","LU2746668461.USD","LU0109394709.USD","LU1629891620.HKD","IE00B2B36J28.USD","LU1280957306.USD","LU1057294990.SGD","MEDI","LU0820561818.USD","LU0385154629.USD","TRUH","LU2756315664.SGD","LU0882574139.USD","IE00BWXC8680.SGD","LU2265009873.SGD","LU0320765992.SGD","LU0133085943.USD","BK4007","LU2237443622.USD","BK4534","SGXZ57979304.SGD","LU0094547139.USD","LU0889565916.HKD","LU2462591350.SGD","LU1983299246.USD","LU0097036916.USD","IE00BKDWB100.SGD","SG9999001176.SGD","SG9999015986.USD","SGXZ51526630.SGD","LU2462157665.USD","LU0061475181.USD","MHIP","FTXH","LU0225283273.USD","LU1366192091.USD","LU1814569148.SGD","LU2552382058.USD","LU0820562030.AUD","LU2237443978.SGD","SG9999015952.SGD","HRTS","IE00BFTCPJ56.SGD","LU1551013342.USD","LU2112291526.USD","LU0345770308.USD","LU2750360641.GBP","CANC","LU0823434740.USD","LU2237443549.SGD","IE0005OL40V9.USD","LU2361045086.USD","LU2237438978.USD","XLV","LU2491050154.USD","LU0256863902.USD","LU0320765059.SGD","LU0471298777.SGD","LU1127390331.HKD","LU2468319806.SGD","IE00BKVL7J92.USD","IE00BKPKM429.USD","LU2089984988.USD","LU2023250330.USD","LU1988902786.USD","VHT","LU0345770993.USD","LU2168564149.EUR","LU0456855351.SGD","IE0002141913.USD","LLY","LU2237443895.HKD","LU2357305700.SGD","LU2471134952.CNY","LU2461242641.AUD","LU2750360997.AUD","SG9999014898.SGD","IE0009355771.USD","IE00B4JS1V06.HKD","LU0316494557.USD","LU0354030438.USD","LU0158827948.USD","LU2552382132.HKD","GB00BDT5M118.USD","LU0058720904.USD","LU2756315318.SGD","NVO","NVOC","ELIL","LU0158827781.USD","WDNA","OZEM","LU0106261372.USD","LU0640476718.USD","GDOC","LU1712237335.SGD","LU2237443382.USD","LU1023059063.AUD","LU1548497426.USD","SG9999014914.USD","LU1979441026.SGD","ILDR","LLYX","SGXZ81514606.USD","LU0079474960.USD","LU0683600562.USD","LU2361044949.HKD","BK4533","LU0353189680.USD","LU1868837136.USD","LU2168564222.USD","LU2023251221.USD","LU0823434583.USD","FHLC","LLYZ","LU2491049909.HKD","LU0823416689.USD","LU2111349929.HKD","IE00B1BXHZ80.USD","ELIS","THNR","LU1868837300.USD","SG9999014906.USD","LU1720051017.SGD","BK4532","LU2471134879.HKD","LU0006306889.USD","NVOH","IE00BK4W5L77.USD","IE00BN29S564.USD","LU1917777945.USD","AGNG","IE00BFSS7M15.SGD","LU2271345857.HKD","LU2456880835.USD","LU1064131342.USD","LU2063271972.USD","LU1804176565.USD","LU0198837287.USD","LU2089284900.SGD","SGXZ31699556.SGD","LU1868836914.USD","LU2236285917.USD","LU1232071149.USD","LU1145028129.USD","LU1267930730.SGD","LU2108987350.USD","IXJ","LU0174119429.USD","LU0417517546.SGD","LU1720051108.HKD","LU2602419157.SGD","LU1069344957.HKD","LU2471134796.USD","BK4599","BK4588","IE0004445239.USD","IHE","LU2896262040.SGD","LU0238689110.USD","IE00B775H168.HKD","IE00B7KXQ091.USD","SG9999015945.SGD","LU0154236417.USD","SG9999013999.USD","LU1093756325.SGD","LU2417539215.USD","LU0353189763.USD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668999182","title":"Novo Nordisk Wins EMA Panel Backing for New Haemophilia A Therapy FREHEMGO","url":"https://stock-news.laohu8.com/highlight/detail?id=2668999182","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668999182?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:57","pubTimestamp":1789664236,"startTime":"0","endTime":"0","summary":"Novo Nordisk ( ($NVO) ) has issued an announcement. Novo Nordisk announced on 17 September 2026 that the European Medicines Agency’s Committee for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-wins-ema-panel-backing-for-new-haemophilia-a-therapy-frehemgo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-wins-ema-panel-backing-for-new-haemophilia-a-therapy-frehemgo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["THNR","BK4599","LU0154236417.USD","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","BK4007","NVOC","BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","OZEM","BK4532","NVOX","BK4588","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668999582","title":"Novo Nordisk A/S Stock (NVO) Moved Up by 3.02% on Sep 17: What Signal Does It Send?","url":"https://stock-news.laohu8.com/highlight/detail?id=2668999582","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668999582?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:15","pubTimestamp":1789661722,"startTime":"0","endTime":"0","summary":"• Novo Nordisk partnered with Orbis Medicine for AI-driven oral cardiometabolic drug discovery.\n• European regulators issued a favorable marketing recommendation for Frehemgo in hemophilia A.\n• The company reported $46.70B in annual revenue and $15.48B in net profit.","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262173629-market-movers-nvo-20260917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","NVO","PPH","IE00BZ1G4Q59.USD","NVOC","THNR","BK4585","LU0154236417.USD","BK4532","BK4007","OZEM","LU1093756168.USD","NVOH","LU1093756325.SGD","BK4588","BK4599","NVOX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}